Fig. 2From: Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitorsMultifaceted interaction of relevant factors and resultant vascular effectBack to article page